Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 8/20 | 0.36 |
| ▸ | RAF1 | P04049 | 6/20 | 0.34 |
| ▸ | BRAF | P15056 | 6/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18394865 | 0.89 | F10 (0.38) | F10PTGS2 | |
| SCHEMBL18412939 | 0.87 | F10 (0.34) | F10RAF1BRAFPTGS2MAP4K1 | |
| SCHEMBL18394446 | 0.86 | F10 (0.35) | F10RAF1BRAFPTGS2MAP4K1 | |
| SCHEMBL20098694 | 0.84 | F10 (0.34) | F10RAF1BRAFPTGS2MAP4K1 | |
| SCHEMBL20098569 | 0.74 | F10 (0.45) | F10PTGS2 | |
| SCHEMBL20580171 | 0.70 | KDM4E (0.47) | LRRK2 | |
| SCHEMBL18412926 | 0.68 | KDM4E (0.38) | — | |
| SCHEMBL18395298 | 0.63 | KDM4E (0.46) | — | |
| SCHEMBL2185640 | 0.60 | HIPK4 (0.48) | PTGS2LRRK2 | |
| SCHEMBL18412924 | 0.60 | KDM4E (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9957281-B2 | Benzodiazepine derivatives as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022221-A1 | BENZODIAZEPINE DERIVATIVES AS RSV INHIBITORS | GABRA5, GABRA1, GABBR2 | F10 1867/4885RAF1 3212/4885BRAF 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.